UNSPSC 51294501: Ivoqualine

This classification denotes an antidepressant agent with the molecular formula C20H26N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W0K2QLU43U, chemically known as 6-methoxy-4-(3-((3s,4r)-3-vinyl-4-piperidyl)propyl)quinoline. but generally known as ivoqualine, which bears US NIH Compound Identifier 3038482. European Medicines Agency schedules Ivoqualine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08359MIG.

UNSPSC 51294501 Ivoqualine is a Commodity code under which state and local governments procure pharmaceutical products, including naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products distributed through established supply chains and wholesaler networks. Recent solicitations show purchasing across health departments, county health agencies, and state HHS commissions for emergency response supplies, routine pharmacy benefit programs, and cooperative purchasing arrangements that serve multiple jurisdictions simultaneously.

Activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building; the county required vendors to handle all shipping and delivery costs, maintain workers' compensation and general liability insurance, and comply with E-Verify and drug-free workplace certification. The Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) exploring direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager arrangements, seeking vendor experience with negotiated net pricing and value-based outcomes agreements for self-insured employers and state agencies. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) for generic pharmaceuticals and OTC products to be distributed across participating state and local facilities in multiple states including Oregon; the RFP required cGMP and Drug Supply Chain Security Act certification, mandatory relationships with at least two of three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), and assessment on a 75-percent price-competitiveness basis with supporting insurance coverage of $5 million general liability and $2 million network security liability.